CO2022002022A2 - Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias - Google Patents
Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratoriasInfo
- Publication number
- CO2022002022A2 CO2022002022A2 CONC2022/0002022A CO2022002022A CO2022002022A2 CO 2022002022 A2 CO2022002022 A2 CO 2022002022A2 CO 2022002022 A CO2022002022 A CO 2022002022A CO 2022002022 A2 CO2022002022 A2 CO 2022002022A2
- Authority
- CO
- Colombia
- Prior art keywords
- tmem16a
- modulators
- treatment
- pyridine derivatives
- respiratory conditions
- Prior art date
Links
- 150000003222 pyridines Chemical class 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 102000003787 Anoctamin-1 Human genes 0.000 abstract 1
- 108090000160 Anoctamin-1 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1910607.9A GB201910607D0 (en) | 2019-07-24 | 2019-07-24 | Compounds |
| GBGB2005739.4A GB202005739D0 (en) | 2020-04-20 | 2020-04-20 | Compounds |
| PCT/GB2020/051778 WO2021014166A1 (en) | 2019-07-24 | 2020-07-24 | Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022002022A2 true CO2022002022A2 (es) | 2022-06-10 |
Family
ID=71948615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0002022A CO2022002022A2 (es) | 2019-07-24 | 2022-02-24 | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220235006A1 (enExample) |
| EP (1) | EP4003516A1 (enExample) |
| JP (1) | JP7583022B2 (enExample) |
| KR (1) | KR20220063162A (enExample) |
| CN (1) | CN114616226B (enExample) |
| AU (1) | AU2020317036A1 (enExample) |
| BR (1) | BR112022001164A2 (enExample) |
| CA (1) | CA3145120A1 (enExample) |
| CL (1) | CL2022000147A1 (enExample) |
| CO (1) | CO2022002022A2 (enExample) |
| CR (1) | CR20220072A (enExample) |
| IL (1) | IL290035A (enExample) |
| MX (1) | MX2022000841A (enExample) |
| PE (1) | PE20221441A1 (enExample) |
| PH (1) | PH12022550181A1 (enExample) |
| WO (1) | WO2021014166A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20221441A1 (es) * | 2019-07-24 | 2022-09-21 | Tmem16A Ltd | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias |
| KR20260025059A (ko) * | 2024-08-13 | 2026-02-23 | 전남대학교산학협력단 | 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050176767A1 (en) * | 2003-10-30 | 2005-08-11 | Laval Chan Chun Kong | Pyridine carboxamide and methods for inhibiting HIV integrase |
| EP3612180B1 (en) * | 2017-04-17 | 2023-10-11 | The Regents of the University of California | Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel tmem16a |
| GB201801355D0 (en) * | 2018-01-26 | 2018-03-14 | Enterprise Therapeutics Ltd | Compounds |
| PE20221441A1 (es) * | 2019-07-24 | 2022-09-21 | Tmem16A Ltd | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias |
-
2020
- 2020-07-24 PE PE2022000119A patent/PE20221441A1/es unknown
- 2020-07-24 EP EP20751234.4A patent/EP4003516A1/en active Pending
- 2020-07-24 KR KR1020227006371A patent/KR20220063162A/ko not_active Ceased
- 2020-07-24 BR BR112022001164A patent/BR112022001164A2/pt not_active Application Discontinuation
- 2020-07-24 CN CN202080053192.6A patent/CN114616226B/zh active Active
- 2020-07-24 PH PH1/2022/550181A patent/PH12022550181A1/en unknown
- 2020-07-24 CR CR20220072A patent/CR20220072A/es unknown
- 2020-07-24 WO PCT/GB2020/051778 patent/WO2021014166A1/en not_active Ceased
- 2020-07-24 AU AU2020317036A patent/AU2020317036A1/en not_active Abandoned
- 2020-07-24 JP JP2022504089A patent/JP7583022B2/ja active Active
- 2020-07-24 CA CA3145120A patent/CA3145120A1/en active Pending
- 2020-07-24 MX MX2022000841A patent/MX2022000841A/es unknown
-
2022
- 2022-01-21 US US17/581,504 patent/US20220235006A1/en active Pending
- 2022-01-21 CL CL2022000147A patent/CL2022000147A1/es unknown
- 2022-01-23 IL IL290035A patent/IL290035A/en unknown
- 2022-02-24 CO CONC2022/0002022A patent/CO2022002022A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220072A (es) | 2022-06-29 |
| MX2022000841A (es) | 2022-06-08 |
| WO2021014166A1 (en) | 2021-01-28 |
| CL2022000147A1 (es) | 2022-10-07 |
| PE20221441A1 (es) | 2022-09-21 |
| JP2022541311A (ja) | 2022-09-22 |
| PH12022550181A1 (en) | 2023-01-16 |
| KR20220063162A (ko) | 2022-05-17 |
| IL290035A (en) | 2022-03-01 |
| CA3145120A1 (en) | 2021-01-28 |
| US20220235006A1 (en) | 2022-07-28 |
| AU2020317036A1 (en) | 2022-03-17 |
| JP7583022B2 (ja) | 2024-11-13 |
| CN114616226A (zh) | 2022-06-10 |
| CN114616226B (zh) | 2025-03-04 |
| EP4003516A1 (en) | 2022-06-01 |
| BR112022001164A2 (pt) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020010552A2 (es) | Compuestos | |
| ECSP20021913A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| CO2019006622A2 (es) | Derivados de pirazol como inhibidores de malt1 | |
| CY1124022T1 (el) | Σχημα χορηγησης για νιτροκατεχολες | |
| UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| UY37435A (es) | Pirrolidinas sustituidas y métodos para usarlas | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| UY37900A (es) | Nuevos derivados de rapamicina | |
| CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| CR20160241A (es) | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b | |
| MX387596B (es) | Degradadores selectivos del receptor de estrógeno y sus usos. | |
| PE20180462A1 (es) | Moduladores cot y metodos de uso de los mismos | |
| CR20160337A (es) | Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b | |
| CY1111758T1 (el) | Τρικυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα γλυκοκορτικοειδους | |
| ECSP15035530A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| CO2021001219A2 (es) | Benzimidazoles sustituidos como inhibidores de pad4 | |
| MX393586B (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| NI201500081A (es) | Derivados de imidazopiridazina como moduladores del receptor gabaa | |
| MX2021002215A (es) | Derivados de tetrahidropiridopirimidina como moduladores de ahr. | |
| MX2019005934A (es) | Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac). | |
| MX372772B (es) | Enonas piridazolilo y pirimidinilo tricíclicas sustituidas con arilo y arilalquilo como moduladores de la inflamación antioxidantes. |